BioEclipse Therapeutics

BioEclipse Therapeutics

BioEclipse is a clinical-stage immunotherapy company using proprietary platform technology to develop a first-in-class immunotherapy that pairs the power of an oncolytic virus with the tumor-locating ability of cytokine-induced killer (CIK) cells.

Claim My Business
Security Type
Common Stock
Min Investment
Mountain View, CA
Offering Date
January 19, 2022
Expected Close Date
April 19, 2022
Target Raise
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

BioEclipse Therapeutics™ is a clinical-stage oncology company that uses its proprietary platform technology to develop the next generation of immuno-oncology therapeutics. Our fundamental premise is that cancer has multiple causes and challenges that requires a multi-mechanistic approach.

We are continuously working to develop a new generation of precise, targeted, immunotherapies that bring hope to patients with advanced cancer who have few treatment options. Foundationally, we have harnessed a refined understanding of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors.

Key Deal Facts

$13.8M raised to date

2 issued/licensed patents from Stanford University: (#10,064,893) & (#9,101,658)

Projected $92.97B immuno-oncology drug market

President & CEO, Pamela R. Contag, Ph.D., recognized by Goldman Sachs and Fortune Magazine, among many others

Board of Directors made up of life science company investors, biopharmaceutical executives with product development and commercial expertise

CRX100 clinical trials underway
Amount Raised : $6,390
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

Common stock is a security that represents ownership in a corporation.

Research Reports

No reports have been submitted

Become a Reporter